"IV immunoglobin treatment at immune thrombocytopenia diagnosis did not lead to a lower rate of chronic immune thrombocytopenia among children, according to results from a randomized clinical trial.

“This will influence clinical care in daily practice; IV immunoglobin treatment should only be given based on individual patient characteristics, like for toddlers who fall often or

"The Phase 1 data published today in the peer-reviewed Journal of Clinical Investigation highlight the unique design of efgartigimod as an Fc fragment modified by our proprietary ABDEG(TM) technology. The drug candidate's binding properties with FcRn are enhanced by the ABDEG mutation, which may contribute to the differentiated pharmacokinetic and pharmacodynamic activity we saw in

"The FDA has accepted Novartis’ supplemental New Drug Application (sNDA) and granted Priority Review designation to Promacta (eltrombopag) in combination with standard immunosuppressive therapy (IST) for first-line treatment of severe aplastic anaemia (SAA), a rare and serious blood condition.

Priority Review designation is used for treatments that address a serious or life-threatening disease or condition

"One young man is on a mission to gather as many power chords as possible for children who are hospitalized.

It's called Power Jacks, which only makes sense because it was created by 13 year-old Jack Lewy.

Lewy is no stranger to Tulane Lakeside Hosptial for Women and Children in Metairie.

In December, Lewy suffered